Mesalamine Reduces Intestinal ACE2 Expression Without Modifying SARS-CoV-2 Infection or Disease Severity in Mice.
作者信息
Alvarado David M, Son Juhee, Thackray Larissa B, Gomez Castro Maria Florencia, Prasad Sarada, Cui Xueyang, Sonnek Naomi M, Diamond Michael S, Ding Siyuan, Ciorba Matthew A
机构信息
From the ∗Inflammatory Bowel Diseases Center, Division of Gastroenterology, Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Department of Molecular Microbiology, Washington University in St. Louis, St. Louis, MO, USA.
出版信息
Inflamm Bowel Dis. 2022 Feb 1;28(2):318-321. doi: 10.1093/ibd/izab274.
Abstract
摘要
相似文献
1
Mesalamine Reduces Intestinal ACE2 Expression Without Modifying SARS-CoV-2 Infection or Disease Severity in Mice.
Inflamm Bowel Dis. 2022 Feb 1;28(2):318-321. doi: 10.1093/ibd/izab274.
2
Mesalamine Reduces Intestinal ACE2 Expression Without Modifying SARS-CoV-2 Infection or Disease Severity in Mice.
bioRxiv. 2021 Aug 2:2021.07.23.453393. doi: 10.1101/2021.07.23.453393.
3
Altered Intestinal ACE2 Levels Are Associated With Inflammation, Severe Disease, and Response to Anti-Cytokine Therapy in Inflammatory Bowel Disease.
Gastroenterology. 2021 Feb;160(3):809-822.e7. doi: 10.1053/j.gastro.2020.10.041. Epub 2020 Nov 5.
4
A pressor dose of angiotensin II has no influence on the angiotensin-converting enzyme 2 and other molecules associated with SARS-CoV-2 infection in mice.
FASEB J. 2021 Mar;35(3):e21419. doi: 10.1096/fj.202100016R.
5
ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury.
Nat Commun. 2021 Nov 23;12(1):6791. doi: 10.1038/s41467-021-27097-8.
6
SARS-CoV-2 deregulates the vascular and immune functions of brain pericytes via Spike protein.
Neurobiol Dis. 2021 Dec;161:105561. doi: 10.1016/j.nbd.2021.105561. Epub 2021 Nov 13.
7
ACE2: from protection of liver disease to propagation of COVID-19.
Clin Sci (Lond). 2020 Dec 11;134(23):3137-3158. doi: 10.1042/CS20201268.
8
Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
High Blood Press Cardiovasc Prev. 2021 Mar;28(2):129-139. doi: 10.1007/s40292-021-00439-9. Epub 2021 Feb 26.
9
Discovery of a AHR pelargonidin agonist that counter-regulates Ace2 expression and attenuates ACE2-SARS-CoV-2 interaction.
Biochem Pharmacol. 2021 Jun;188:114564. doi: 10.1016/j.bcp.2021.114564. Epub 2021 Apr 17.
10
ACE2 in the renin-angiotensin system.
Clin Sci (Lond). 2020 Dec 11;134(23):3063-3078. doi: 10.1042/CS20200478.
引用本文的文献
1
Spatial immune landscapes of SARS-CoV-2 gastrointestinal infection: macrophages contribute to local tissue inflammation and gastrointestinal symptoms.
Front Cell Dev Biol. 2024 Jul 17;12:1375354. doi: 10.3389/fcell.2024.1375354. eCollection 2024.
2
SARS-CoV-2 Omicron BA.1 Variant Infection of Human Colon Epithelial Cells.
Viruses. 2024 Apr 19;16(4):634. doi: 10.3390/v16040634.
3
Calpain-2 mediates SARS-CoV-2 entry via regulating ACE2 levels.
mBio. 2024 Mar 13;15(3):e0228723. doi: 10.1128/mbio.02287-23. Epub 2024 Feb 13.
4
Persistent SARS-CoV-2 Infection, EBV, HHV-6 and Other Factors May Contribute to Inflammation and Autoimmunity in Long COVID.
Viruses. 2023 Jan 31;15(2):400. doi: 10.3390/v15020400.
5
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case-Control Study (COVID-19-EII).
J Clin Med. 2022 Dec 19;11(24):7540. doi: 10.3390/jcm11247540.
6
I've looked at gut from both sides now: Gastrointestinal tract involvement in the pathogenesis of SARS-CoV-2 and HIV/SIV infections.
Front Immunol. 2022 Aug 12;13:899559. doi: 10.3389/fimmu.2022.899559. eCollection 2022.
7
Targeting the Gut Microbiota in Coronavirus Disease 2019: Hype or Hope?
Gastroenterology. 2022 Jan;162(1):9-16. doi: 10.1053/j.gastro.2021.09.009. Epub 2021 Sep 8.
本文引用的文献
1
Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry.
Gastroenterology. 2022 Jan;162(1):316-319.e5. doi: 10.1053/j.gastro.2021.09.011. Epub 2021 Sep 14.
2
Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell.
Cell Rep. 2021 Jul 13;36(2):109364. doi: 10.1016/j.celrep.2021.109364. Epub 2021 Jun 23.
3
Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System.
Gut. 2021 Sep;70(9):1657-1664. doi: 10.1136/gutjnl-2021-324356. Epub 2021 Mar 22.
4
Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms.
Gastroenterology. 2021 Jun;160(7):2435-2450.e34. doi: 10.1053/j.gastro.2021.02.056. Epub 2021 Mar 4.
5
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.
Nat Med. 2021 Apr;27(4):717-726. doi: 10.1038/s41591-021-01294-w. Epub 2021 Mar 4.
6
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry.
Ann Rheum Dis. 2021 Jul;80(7):930-942. doi: 10.1136/annrheumdis-2020-219498. Epub 2021 Jan 27.
7
Altered Intestinal ACE2 Levels Are Associated With Inflammation, Severe Disease, and Response to Anti-Cytokine Therapy in Inflammatory Bowel Disease.
Gastroenterology. 2021 Feb;160(3):809-822.e7. doi: 10.1053/j.gastro.2020.10.041. Epub 2020 Nov 5.
8
Effect of IBD medications on COVID-19 outcomes: results from an international registry.
Gut. 2021 Apr;70(4):725-732. doi: 10.1136/gutjnl-2020-322539. Epub 2020 Oct 20.
9
SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function.
Nat Immunol. 2020 Nov;21(11):1327-1335. doi: 10.1038/s41590-020-0778-2. Epub 2020 Aug 24.
10
TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes.
Sci Immunol. 2020 May 13;5(47). doi: 10.1126/sciimmunol.abc3582.
Zotero 插件